Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

AI drives decision inputs: In 2025, both big pharma and small pharma use advanced predictive modeling, digital twins, and AI-powered analytics throughout R&D and regulatory processes. This reduces ...

The OCTDI under the Office of the Vice President for Health Sciences serves as a hub interconnecting interdisciplinary clinical trial research collaborations among UB investigators and our regional ...

The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur ...

to simplify execution and accelerate the clinical development process.” To learn more about the Medidata Experiences, please visit here. Medidata is powering smarter treatments and healthier people ...

The Company’s presentation showcased promising early data on the viability and potency of cells from its proprietary Master Cell Bank (“MCB”). The MCB represents a valuable and key strategic asset in ...

The draft guidance, which is touted as a way to reduce the cost and time-associated burden of biosimilar development, has ...

With the continuing cuts to US Food and Drug Administration (FDA) staffing, the pharmaceutical and biotechnology industries are communicating increasing concern about potential product development ...

During IDWeek 2025 in Atlanta, Georgia, Loren G. Miller, MD, MPH, investigator at The Lundquist Institute for Biomedical ...